Context Therapeutics
CNTX
25 hedge funds and large institutions have $5.43M invested in Context Therapeutics in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 3 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
35% more capital invested
Capital invested by funds: $4.02M → $5.43M (+$1.41M)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
4% more funds holding
Funds holding: 24 → 25 (+1)
2.36% more ownership
Funds ownership: 22.28% → 24.64% (+2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$232K |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$150K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$25.2K |
| 4 |
JFG
Jefferies Financial Group
New York
|
+$12.9K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$11.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWM
Aspire Wealth Management
Waltham,
Massachusetts
|
-$11.3K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$10.7K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$944 |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$335 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$123 |
CNTX Hedge Fund Activity: Q1 2024 in Review
25 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Context Therapeutics (CNTX) for Q1 2024, worth a combined $5.43M — up 35% from $4.02M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CNTX positions and 3 closed out — a net gain of 1 holder — while 6 added to existing stakes and 2 trimmed.
The largest buyer was ADAR1 Capital Management, opening a new position worth an estimated $232K. The largest seller was Aspire Wealth Management, exiting entirely with an estimated $11.3K sold.
- 25 institutional investors held Context Therapeutics (CNTX) as of Q1 2024, up from 24 in Q4 2023.
- Funds reported $5.43M of Context Therapeutics stock for Q1 2024, up 35% quarter-over-quarter.
- 4 funds opened new Context Therapeutics positions in Q1 2024 and 3 closed out, a net change of +1 holder.
- The largest Context Therapeutics buyer in Q1 2024 was ADAR1 Capital Management, an estimated $232K added.
- The largest Context Therapeutics seller in Q1 2024 was Aspire Wealth Management, an estimated $11.3K sold.
Based on aggregated 13F filings for Q1 2024.